SCYNEXIS, Inc (SCYX)

JERSEY CITY, N.J., Nov. 29, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will host a hospital pipeline update for its novel antifungal, ibrexafungerp, during a webcast on Monday, December 6, at 10 a.m. ET. The webcast event will feature a presentation from Martin Hoenigl, M.D., Associate Professor, FECMM, Division of Infectious Disea

Patients receiving one-day treatment with oral ibrexafungerp had significantly higher rates of clinical cure, mycological eradication, and clinical improvement at Day-10 compared to placebo-treated patients. Ibrexafungerp demonstrated sustained clinical effect at Day-25 follow-up with 73.9% of treated patients achieving a complete resolution of signs and symptoms.The Phase 3 VANISH clinical trial program (VANISH-303 and VANISH-306) supported the approval of BREXAFEMME by the U.S. Food and Drug A

Gainers Greenland Technologies Holding Corporation (NASDAQ: GTEC) shares surged 90.2% to close at $9.89 on Friday. Greenland ...

Gainers SCYNEXIS (NASDAQ:SCYX) stock rose 15.69% to $7.15 during Friday's regular session. As of 12:30 EST, this ...

Gainers Greenland Technologies Holding Corporation (NASDAQ: GTEC) shares jumped 75.4% to $9.17. Greenland Technologies ...

'The Big Short' guy is bearish. But not on this trio of plays.

Gainers Casper Sleep Inc. (NYSE: CSPR) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be ...

Gainers Tricida (NASDAQ:TCDA) shares rose 15.2% to $6.29 during Monday's regular session. Tricida's stock is trading at a volume of ...

Scynexis (SCYX) delivered earnings and revenue surprises of 92.41% and 3.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

BREXAFEMME® (ibrexafungerp tablets) net sales of $0.5 million generated since August, with IQVIA reporting 1,006 prescriptions in partial Q3; momentum is continuing into Q4 with an additional 1,100 prescriptions reported in October.BREXAFEMME is now covered by commercial insurance plans representing more than 30% of commercially insured lives, exceeding internal expectations.Intravenous (IV) ibrexafungerp is ready to advance to the next stage of clinical development following successful Phase 1

Safety and tolerability of new liposomal IV formulation confirmed to reach target exposure in single ascending dose (SAD) and multiple ascending dose (MAD) studyJERSEY CITY, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the successful completion of a Phase 1 clinical study to evaluate the safety, tolerability and pharmacokineti

JERSEY CITY, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 10, 2021, to provide a corporate update and discuss the Company’s financial results for the third quarter ended September 30, 2021. Conference call and webcast details: Investors (dom

In the Phase 3 VANISH-303 study, ibrexafungerp demonstrated significantly higher rates of clinical cure and infection eradication versus placebo.Post hoc analysis found ibrexafungerp demonstrated consistent efficacy in important patient sub-populations, characterized by race/ethnicity and body mass index.In the Phase 2 DOVE study, ibrexafungerp demonstrated similar efficacy to the current standard of care at the Day 10 visit with sustained efficacy at the Day 25 follow-up visit. JERSEY CITY, N.J

JERSEY CITY, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced presentations of a pooled data analysis from its successful VANISH clinical development program during two October medical meetings: the Nurse Practitioners in Women’s Health (NPWH) 24th Annual Premier Women’s Healthcare Conference and the 4th Congress of the Internatio

In vivo data demonstrated response rate for ibrexafungerp similar to current standard of care options for the treatment of mucormycosisCombination of ibrexafungerp with current therapies showed significant enhancement in median survival time and overall survival when compared with standard of care monotherapies JERSEY CITY, N.J., Oct. 11, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and

Pre-clinical data on ibrexafungerp for mucormycosis also will be shared via an oral presentationJERSEY CITY, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced two poster presentations of interim data from its ongoing FURI and CARES studies, evaluating oral ibrexafungerp for the treatment of patients with refractory mucocutaneous an

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, today announced that 10 of its member companies will present data from their clinical and research programs at IDWeek 2021 taking place virtually from September 29-October 3, 2021. AWG members are presenting a total of 23 poster presentations and 3 oral abstract presentations.

Scynexis Inc(NASDAQ: SCYX) announced anoral presentation of interim data analysesfrom its ongoing Phase 3 FURI ...

Subpopulation analysis of 74 patients from ongoing Phase 3 FURI study demonstrated similar efficacy against multiple serious fungal infections

Subpopulation analysis of 74 patients from ongoing Phase 3 FURI study demonstrated similar efficacy against multiple serious fungal infectionsJERSEY CITY, N.J., Sept. 29, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced an oral presentation of analyses of interim data from its ongoing Phase 3 FURI study showing favorable clinical activity of ora

Analysis of subpopulations from a total of 74 patients evaluated to date from FURI includes outcomes by disease, bone and joint infections, and mouth and throat candidiasis

Analysis of subpopulations from a total of 74 patients evaluated to date from FURI includes outcomes by disease, bone and joint infections, and mouth and throat candidiasisJERSEY CITY, N.J., Sept. 23, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced one oral and two poster presentations of interim data from its Phase 3 FURI study, evaluating ora

A look at the shareholders of SCYNEXIS, Inc. ( NASDAQ:SCYX ) can tell us which group is most powerful. Generally...

Submission is part of the Hansoh Pharma licensing agreement and strategic partnership to research, develop and commercialize ibrexafungerp in the Greater China region

We're definitely into long term investing, but some companies are simply bad investments over any time frame. We don't...